{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T11:55:23Z","timestamp":1791374123897,"version":"4.3.1"},"reference-count":34,"publisher":"Galenos Yayinevi","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mirt"],"DOI":"10.4274\/mirt.galenos.2026.80037","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T06:55:42Z","timestamp":1787036142000},"source":"Crossref","is-referenced-by-count":0,"title":["Comparative Performance of 18F-FDG PET\/CT and 68Ga-FAPI PET\/CT in TENIS Syndrome in Treated Differentiated Thyroid Carcinoma"],"prefix":"10.4274","author":[{"given":"Jayantilal Bhagirath","family":"Bhad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manjit","family":"Sarma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usha","family":"Menon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramkesh","family":"R.","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parvathy","family":"Pavithran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Awiral","family":"Saxena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjana","family":"Sajeev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. Venkata Sai Ram","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Padma","family":"Subramanyam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanmuga","family":"Sundaram P","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2811","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","unstructured":"1. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17-48.","journal-title":"CA Cancer J Clin"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1016\/S0140-6736(16)30172-6","article-title":"Thyroid cancer","volume":"388","author":"Cabanillas","year":"2016","unstructured":"2. Cabanillas ME, McFadden DG, Durante C. Thyroid cancer. Lancet. 2016;388:2783-2795.","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer","volume":"26","author":"Haugen","year":"2016","unstructured":"3. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26:1-133.","journal-title":"Thyroid"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1089\/thy.2018.0597","article-title":"Controversies, consensus, and collaboration in the use of 131I therapy in differentiated thyroid cancer: a joint statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Im-aging, and the European Thyroid Association","volume":"29","author":"Tuttle","year":"2019","unstructured":"4. Tuttle RM, Ahuja S, Avram AM, Bernet VJ, Bourguet P, Daniels GH, Dillehay G, Draganescu C, Flux G, F\u00fchrer D, Giovanella L, Greenspan B, Luster M, Muylle K, Smit JWA, Van Nostrand D, Verburg FA, Heged\u00fcs L. Controversies, consensus, and collaboration in the use of 131I therapy in differentiated thyroid cancer: a joint statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Im-aging, and the European Thyroid Association. Thyroid. 2019;29:461-470.","journal-title":"Thyroid"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1001\/jama.2017.2719","article-title":"Trends in thyroid cancer incidence and mor-tality in the United States, 1974-2013","volume":"317","author":"Lim","year":"2017","unstructured":"5. Lim H, Devesa SS, Sosa JA, Check D, Kitahara CM. Trends in thyroid cancer incidence and mor-tality in the United States, 1974-2013. JAMA. 2017;317:1338-1348.","journal-title":"JAMA"},{"key":"ref5","unstructured":"6. Vaisman F, Tuttle RM. Clinical assessment and follow-up of differentiated thyroid cancer pa-tients. Best Pract Res Clin Endocrinol Metab. 2013;27:503-512."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1210\/jc.2005-2838","article-title":"Long-term outcome of 444 patients with distant metasta-ses from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy","volume":"91","author":"Durante","year":"2006","unstructured":"7. Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, Caillou B, Ricard M, Lumbroso JD, De Vathaire F, Schlumberger M. Long-term outcome of 444 patients with distant metasta-ses from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006;91:2892-2899.","journal-title":"J Clin Endocrinol Metab"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thy-roid cancer","volume":"372","author":"Schlumberger","year":"2015","unstructured":"8. Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, Habra MA, Newbold K, Shah MH, Hoff AO, Gianoukakis AG, Kiyota N, Taylor MH, Kim SB, Krzyzanowska MK, Dutcus CE, de las Heras B, Zhu J, Sherman SI. Lenvatinib versus placebo in radioiodine-refractory thy-roid cancer. N Engl J Med. 2015;372:621-630.","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/S0140-6736(13)60109-9","article-title":"Progress in molecular-based management of differenti-ated thyroid cancer","volume":"381","author":"Xing","year":"2013","unstructured":"9. Xing M, Haugen BR, Schlumberger M. Progress in molecular-based management of differenti-ated thyroid cancer. Lancet. 2013;381:1058-1069.","journal-title":"Lancet"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1210\/jc.2005-1534","article-title":"A retrospective review of the role of FDG-PET in the management of patients with metastatic thyroid cancer","volume":"91","author":"Robbins","year":"2006","unstructured":"10. Robbins RJ, Larson SM, Sinha N, Shaha A, Divgi C, Pentlow KS, et al. A retrospective review of the role of FDG-PET in the management of patients with metastatic thyroid cancer. J Clin Endo-crinol Metab. 2006;91:498-505.","journal-title":"J Clin Endo-crinol Metab"},{"key":"ref10","unstructured":"11. Feine U, Lietzenmayer R, Hanke JP, Held J, W\u00f6hrle H, M\u00fcller-Schauenburg W. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med. 1996;37:1468-1472."},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12. Wang W, Larson SM, Fazzari M, Tickoo SK, Kolbert K, Sgouros G, Yeung H, Macapinlac H, Rosai J, Robbins RJ. Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab. 2000;85:1107-1113.","DOI":"10.1210\/jcem.85.3.6458"},{"key":"ref12","unstructured":"13. Robbins RJ, Schlumberger MJ. The evolving role of (131)I for the treatment of differentiated thy-roid carcinoma. J Nucl Med. 2005;46 Suppl 1:28S-37S."},{"key":"ref13","unstructured":"14. Palmedo H, Bucerius J, Joe A, Strunk H, Hortling N, Meyka S, Roedel R, Wolff M, Wardelmann E, Biersack HJ, Jaeger U. Integrated PET\/CT in differentiated thyroid cancer: diagnostic accuracy and impact on patient management. J Nucl Med. 2006;47:616-624."},{"key":"ref14","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1002\/hed.21492","article-title":"FDG-PET in papillary thyroid carcinoma: a systematic review and meta-analysis","volume":"33","author":"Miller","year":"2011","unstructured":"15. Miller ME, Wang P, Tuttle RM, Grewal RK. FDG-PET in papillary thyroid carcinoma: a systematic review and meta-analysis. Head Neck. 2011;33:562-565.","journal-title":"Head Neck"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"801","DOI":"10.2967\/jnumed.119.227967","article-title":"68Ga-FAPI PET\/CT: tracer uptake in 28 different kinds of cancer","volume":"60","author":"Kratochwil","year":"2019","unstructured":"16. Kratochwil C, Flechsig P, Lindner T, Abderrahim L, Altmann A, Mier W, Adeberg S, Rathke H, R\u00f6hrich M, Winter H, Plinkert PK, Marme F, Lang M, Kauczor HU, J\u00e4ger D, Debus J, Haberkorn U, Giesel FL. 68Ga-FAPI PET\/CT: tracer uptake in 28 different kinds of cancer. J Nucl Med. 2019;60:801-805.","journal-title":"J Nucl Med"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"386","DOI":"10.2967\/jnumed.118.215913","article-title":"68Ga-FAPI PET\/CT: biodistribution and preliminary dosimetry estimate of 2 DOTAContaining FAP-targeting agents in patients with various cancers","volume":"60","author":"Giesel","year":"2019","unstructured":"17. Giesel FL, Kratochwil C, Lindner T, Marschalek MM, Loktev A, Lehnert W, Debus J, J\u00e4ger D, Flechsig P, Altmann A, Mier W, Haberkorn U. 68Ga-FAPI PET\/CT: biodistribution and preliminary dosimetry estimate of 2 DOTAContaining FAP-targeting agents in patients with various cancers. J Nucl Med. 2019;60:386-392.","journal-title":"J Nucl Med"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1007\/s00259-020-04882-z","article-title":"Fibroblast imaging of hepatic carcinoma with 68Ga-FAPI-04 PET\/CT: a pilot study in patients with suspected hepatic nodules","volume":"48","author":"Shi","year":"2021","unstructured":"18. Shi X, Xing H, Yang X, Li F, Yao S, Zhang H, Zhao H, Hacker M, Huo L, Li X. Fibroblast imaging of hepatic carcinoma with 68Ga-FAPI-04 PET\/CT: a pilot study in patients with suspected hepatic nodules. Eur J Nucl Med Mol Imaging. 2021;48:196-203.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1148\/radiol.2020203275","article-title":"Comparison of 68Ga-FAPI and 18F-FDG uptake in gastric, duodenal, and colorectal cancers","volume":"298","author":"Pang","year":"2021","unstructured":"19. Pang Y, Zhao L, Luo Z, Hao B, Wu H, Lin Q, Sun L, Chen H. Comparison of 68Ga-FAPI and 18F-FDG uptake in gastric, duodenal, and colorectal cancers. Radiology. 2021;298:393-402.","journal-title":"Radiology"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1007\/s00259-020-05132-y","article-title":"FAPi, and the head-to-head comparison with [18F]F-FDG PET\/CT in patients with various cancers","volume":"48","author":"Ballal","year":"2021","unstructured":"20. Ballal S, Yadav MP, Moon ES, Kramer VS, Roesch F, Kumari S, Tripathi M, ArunRaj ST, Sarswat S, Bal C. Biodistribution, pharmacokinetics, dosimetry of [68Ga]Ga-DOTA.SA.FAPi, and the head-to-head comparison with [18F]F-FDG PET\/CT in patients with various cancers. Eur J Nucl Med Mol Imaging. 2021;48:1915-1931.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref20","unstructured":"21. Alevroudis E, Skoura E, Skarlatos A, Gkika E, Exadaktylos N, Zissimopoulos A, et al. Head-to-head comparison of [18F]FDG and [68Ga]Ga-FAPI-74 PET\/CT in radioiodine-refractory differen-tiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2024;51(Suppl 1):S102."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"3590","DOI":"10.1210\/jc.2007-0444","article-title":"Ultrasound criteria of malignancy for cervical lymph nodes in patients fol-lowed up for differentiated thyroid cancer","volume":"92","author":"Leboulleux","year":"2007","unstructured":"22. Leboulleux S, Girard E, Rose M, Travagli JP, Sabbah N, Caillou B, Hartl DM, Lassau N, Baudin E, Schlumberger M. Ultrasound criteria of malignancy for cervical lymph nodes in patients fol-lowed up for differentiated thyroid cancer. J Clin Endocrinol Metab. 2007;92:3590-3594.","journal-title":"J Clin Endocrinol Metab"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1200\/JCO.2014.59.8391","article-title":"Extent of surgery for papillary thy-roid cancer is not associated with survival: an analysis of 61,775 patients","volume":"33","author":"Adam","year":"2015","unstructured":"23. Adam MA, Pura J, Gu L, Dinan MA, Tyler DS, Reed SD, et al. Extent of surgery for papillary thy-roid cancer is not associated with survival: an analysis of 61,775 patients. J Clin Oncol. 2015;33:2370-2375.","journal-title":"J Clin Oncol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1089\/thy.2011.0011","article-title":"Ultrasonographically detected small thyroid bed nodules identified after total thyroidectomy for differentiated thyroid cancer seldom show clinically significant structural progression","volume":"21","author":"Rondeau","year":"2011","unstructured":"24. Rondeau G, Fish S, Hann LE, Fagin JA, Tuttle RM. Ultrasonographically detected small thyroid bed nodules identified after total thyroidectomy for differentiated thyroid cancer seldom show clinically significant structural progression. Thyroid. 2011;21:845-853.","journal-title":"Thyroid"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1089\/thy.2012.0352","article-title":"Thyroglobulin antibody status and 131I whole-body scan results predict the need for further radioiodine therapy in patients with low stimulated thyroglobulin levels","volume":"23","author":"Robenshtok","year":"2013","unstructured":"25. Robenshtok E, Grewal RK, Fish S, Sabra MM, Tuttle RM. Thyroglobulin antibody status and 131I whole-body scan results predict the need for further radioiodine therapy in patients with low stimulated thyroglobulin levels. Thyroid. 2013;23:436-442.","journal-title":"Thyroid"},{"key":"ref25","unstructured":"26. Schlumberger M, Tubiana M, De Vathaire F, Hill C, Gardet P, Travagli JP, et al. Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carci-noma. J Nucl Med. 1996;37:598-605."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1210\/jc.2012-1169","article-title":"Skeletal-related events due to bone metastases from differentiated thyroid cancer","volume":"97","author":"Farooki","year":"2012","unstructured":"27. Farooki A, Leung V, Tala H, Tuttle RM. Skeletal-related events due to bone metastases from differentiated thyroid cancer. J Clin Endocrinol Metab. 2012;97:2433-2439.","journal-title":"J Clin Endocrinol Metab"},{"key":"ref27","unstructured":"28. Wang Y, Chen L, Liu X, Zhao L, Sun X, Luo Z, et al. Fibroblast activation protein expression in thyroid cancer and its clinical significance. Front Med (Lausanne). 2023;10:1279978."},{"key":"ref28","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41568-019-0238-1","article-title":"A framework for advancing our un-derstanding of cancer-associated fibroblasts","volume":"20","author":"Sahai","year":"2020","unstructured":"29. Sahai E, Astsaturov I, Cukierman E, DeNardo DG, Egeblad M, Evans RM, Fearon D, Greten FR, Hingorani SR, Hunter T, Hynes RO, Jain RK, Janowitz T, Jorgensen C, Kimmelman AC, Kolonin MG, Maki RG, Powers RS, Pur\u00e9 E, Ramirez DC, Scherz-Shouval R, Sherman MH, Stewart S, Tlsty TD, Tuveson DA, Watt FM, Weaver V, Weeraratna AT, Werb Z. A framework for advancing our un-derstanding of cancer-associated fibroblasts. Nat Rev Cancer. 2020;20:174-186.","journal-title":"Nat Rev Cancer"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/nrc.2016.73","article-title":"The biology and function of fibroblasts in cancer","volume":"16","author":"Kalluri","year":"2016","unstructured":"30. Kalluri R. The biology and function of fibroblasts in cancer. Nat Rev Cancer. 2016;16:582-598.","journal-title":"Nat Rev Cancer"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.2967\/jnumed.118.210443","article-title":"Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein","volume":"59","author":"Lindner","year":"2018","unstructured":"31. Lindner T, Loktev A, Altmann A, Giesel F, Kratochwil C, Debus J, J\u00e4ger D, Mier W, Haberkorn U. Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein. J Nucl Med. 2018;59:1415-1422.","journal-title":"J Nucl Med"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.2967\/jnumed.121.262426","article-title":"Correlation of 68Ga-FAPi-46 PET biodistribution with FAP expression by immunohistochemistry in patients with solid cancers: interim analysis of a prospective translational exploratory study","volume":"63","author":"Mona","year":"2022","unstructured":"32. Mona CE, Benz MR, Hikmat F, Grogan TR, Lueckerath K, Razmaria A, Riahi R, Slavik R, Girgis MD, Carlucci G, Kelly KA, French SW, Czernin J, Dawson DW, Calais J. Correlation of 68Ga-FAPi-46 PET biodistribution with FAP expression by immunohistochemistry in patients with solid cancers: interim analysis of a prospective translational exploratory study. J Nucl Med. 2022;63:1021-1026.","journal-title":"J Nucl Med"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1007\/s00268-002-6612-1","article-title":"Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients","volume":"26","author":"Hay","year":"2002","unstructured":"33. Hay ID, Thompson GB, Grant CS, Bergstralh EJ, Dvorak CE, Gorman CA, Maurer MS, McIver B, Mullan BP, Oberg AL, Powell CC, van Heerden JA, Goellner JR. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg. 2002;26:879-885.","journal-title":"World J Surg"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1089\/thy.2015.0315","article-title":"The impact of age on risk stratification for thyroid cancer","volume":"26","author":"Nixon","year":"2016","unstructured":"34. Nixon IJ, Wang LY, Palmer FL, Tuttle RM, Shaha AR, Shah JP, et al. The impact of age on risk stratification for thyroid cancer. Thyroid. 2016;26:373-380.","journal-title":"Thyroid"}],"container-title":["Molecular Imaging and Radionuclide Therapy"],"original-title":[],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T11:28:15Z","timestamp":1791372495000},"score":1,"resource":{"primary":{"URL":"https:\/\/mirt.tsnmjournals.org\/articles\/comparative-performance-of-lesssupgreater18lesssupgreaterf-fdg-petct-and-lesssupgreater68lesssupgreaterga-fapi-petct-in-tenis-syndrome-in-treated-differentiated-thyroid-carcinoma\/doi\/mirt.galenos.2026.80037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":34,"URL":"https:\/\/doi.org\/10.4274\/mirt.galenos.2026.80037","relation":{},"ISSN":["2146-1414","2147-1959"],"issn-type":[{"value":"2146-1414","type":"print"},{"value":"2147-1959","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,18]]}}}